Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Aliskiren/HCTZ switch study in patients not adequately responding to candesartan/HCTZ
2008-005810-39Phase 3Completed
- Sponsor
- Novartis
- Start
- Nov 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of aliskiren + hydrochlorothiazide in essential hypertension, sponsored by Novartis. Primary endpoint: Change in trough mean sitting diastolic blood pressure. Started Nov 2008; status: completed.
02
Drugs
aliskiren + hydrochlorothiazide
03
Conditions
essential hypertension
Beyond the preview
Go deeper on 2008-005810-39.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-005810-39.